Competitive Fitness Assays Indicate that the E138A Substitution in HIV-1 Reverse Transcriptase Decreases In Vitro Susceptibility to Emtricitabine | Zendy

Nicolas SluisCremer | Zendy; Kelly Huber | Zendy; Chanson J. Brumme | Zendy; P. Richard Harrigan | Zendy

Open Access

Competitive Fitness Assays Indicate that the E138A Substitution in HIV-1 Reverse Transcriptase Decreases In Vitro Susceptibility to Emtricitabine

Author(s) -

Nicolas SluisCremer,

Kelly Huber,

Chanson J. Brumme,

P. Richard Harrigan

Publication year - 2014

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02114-13

Subject(s) - etravirine , rilpivirine , emtricitabine , reverse transcriptase , virology , reverse transcriptase inhibitor , nucleoside reverse transcriptase inhibitor , tenofovir , human immunodeficiency virus (hiv) , biology , nucleoside , in vitro , lamivudine , virus , genetics , rna , antiretroviral therapy , viral load , gene , hepatitis b virus

We characterized the relative fitness of multiple nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI)-resistant HIV-1 variants in the presence of etravirine (ETV), rilpivirine (RPV), and/or the nucleoside RT inhibitor emtricitabine (FTC) by simultaneous competitive culture and 454 deep sequencing. The E138A substitution, typically associated with decreased virologic responses to ETV- and RPV-containing regimens, confers a clear fitness advantage to the virus in the presence of FTC and decreases FTC susceptibility 4.7-fold.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research